AI assistant
Episurf Regulatory Filings 2021
3157_iss_2021-04-29_13eee9b7-5b2d-4e21-b09b-7c884f7b869d.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
New European patent approval for Episurf Medical
The European patent office EPO has announced its intention to grant another European patent for Episurf Medical (NASDAQ: EPIS B). The patent, entitled "Implant comprising a positioning mark" relates to an important feature of the Episealer® implant for accurate positioning in the joint.
"This strengthens the IP protection in the European market for the Episealer® knee and ankle implants", comments Katarina Flodström, COO, Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69 Email: [email protected]
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's μiFidelity® system enables implants to be costefficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14:00 CEST on 29 April 2021.